Artivion (AORT) Expected to Announce Earnings on Thursday

Artivion (NYSE:AORT) is projected to issue its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of $0.14 per share and revenue of $116.4190 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

Artivion Stock Performance

Shares of Artivion stock opened at $40.40 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.93 and a quick ratio of 2.88. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of -168.33 and a beta of 1.59. Artivion has a 1 year low of $21.97 and a 1 year high of $48.25. The firm’s 50-day moving average is $43.97 and its 200 day moving average is $42.79.

Insider Buying and Selling at Artivion

In other news, CEO James P. Mackin sold 30,921 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $45.56, for a total value of $1,408,760.76. Following the completion of the sale, the chief executive officer owned 800,993 shares of the company’s stock, valued at approximately $36,493,241.08. This represents a 3.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jean F. Holloway sold 7,315 shares of the company’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $45.30, for a total value of $331,369.50. Following the sale, the senior vice president owned 156,093 shares of the company’s stock, valued at approximately $7,071,012.90. This represents a 4.48% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 196,243 shares of company stock worth $8,889,334 over the last quarter. Insiders own 8.10% of the company’s stock.

Hedge Funds Weigh In On Artivion

A number of large investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. lifted its position in Artivion by 144.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock valued at $24,510,000 after acquiring an additional 317,518 shares during the last quarter. Two Sigma Investments LP grew its holdings in shares of Artivion by 235.5% during the third quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock valued at $18,906,000 after buying an additional 313,446 shares during the last quarter. Voloridge Investment Management LLC increased its position in shares of Artivion by 442.9% in the 3rd quarter. Voloridge Investment Management LLC now owns 220,076 shares of the company’s stock valued at $9,318,000 after acquiring an additional 179,541 shares during the period. Invesco Ltd. lifted its position in Artivion by 40.8% during the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after acquiring an additional 139,370 shares during the period. Finally, Osterweis Capital Management Inc. increased its holdings in shares of Artivion by 99.7% in the third quarter. Osterweis Capital Management Inc. now owns 240,772 shares of the company’s stock valued at $10,194,000 after purchasing an additional 120,192 shares during the period. 86.37% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on AORT shares. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 price objective on shares of Artivion in a report on Monday, February 2nd. Wall Street Zen downgraded Artivion from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artivion in a report on Wednesday, January 21st. Oppenheimer reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Artivion in a report on Friday, November 7th. Finally, Citizens Jmp raised their price objective on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.11.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.